Oregon Public Employees Retirement Fund Purchases 158,533 Shares of Pfizer Inc. $PFE

Oregon Public Employees Retirement Fund increased its position in Pfizer Inc. (NYSE:PFE) by 32.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 649,842 shares of the biopharmaceutical company’s stock after acquiring an additional 158,533 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Pfizer were worth $16,558,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Capital Advisory Group Advisory Services LLC raised its position in shares of Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 388 shares during the period. Citizens National Bank Trust Department grew its stake in Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after buying an additional 395 shares in the last quarter. Peak Asset Management LLC raised its holdings in Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after acquiring an additional 402 shares during the period. Able Wealth Management LLC lifted its position in shares of Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock worth $512,000 after acquiring an additional 413 shares in the last quarter. Finally, Boltwood Capital Management boosted its holdings in shares of Pfizer by 0.7% in the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after acquiring an additional 420 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 data for a PADCEV + Keytruda bladder‑cancer combo bolsters Pfizer’s oncology franchise and revenue outlook; clinical validation can drive upside for PFE if regulatory and commercial plans follow. Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment
• Positive Sentiment: Real‑world breast cancer study update signals Pfizer is pushing strategically in the HER2‑positive space — a reminder of ongoing pipeline commercialization opportunities beyond legacy products. Pfizer’s Real‑World Breast Cancer Study Signals Strategic Push in HER2-Positive Market
• Positive Sentiment: Coverage of Pfizer’s AI and precision‑oncology deals highlights a shift in the investment story toward higher‑growth, tech‑enabled oncology programs — can improve long‑term growth perception. How Pfizer’s AI and Precision Oncology Deals Have Changed Its Investment Story
• Positive Sentiment: Partnership with Gordian Bio to probe new obesity targets strengthens Pfizer’s exposure to the high‑growth weight‑loss drug market — a strategic priority highlighted in recent sector narratives. Pfizer partners Gordian Bio to probe new obesity targets
• Positive Sentiment: Broader healthcare sector rebound (VHT coverage) is attracting flows to undervalued pharma names like Pfizer, supporting multiple expansion and demand for dividend/defensive stocks. This ETF Is Proof That the Healthcare Rebound Is Real
• Neutral Sentiment: JPMorgan Healthcare Conference preview: JPM will likely produce company updates and M&A headlines that can move PFE intraday — a near‑term volatility catalyst but outcome‑dependent. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Unusual options flow: heavy activity in March PFE puts (March 20 $29 put highest Vol/OI) — could reflect hedging or directional bearish bets; watch open interest and dealer delta for short‑term price pressure. Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On
• Negative Sentiment: Analyst/retail pieces predicting other healthcare stocks will outperform Pfizer and commentary about a recent ~6% drop signal negative sentiment and may pressure PFE if doubts about growth persist. Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 Pfizer’s Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?

Pfizer Stock Up 0.7%

Shares of NYSE PFE opened at $25.48 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average of $25.26 and a 200-day moving average of $24.95. The firm has a market capitalization of $144.84 billion, a price-to-earnings ratio of 14.81 and a beta of 0.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s payout ratio is 100.00%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on PFE shares. Morgan Stanley decreased their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Scotiabank assumed coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $27.88.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.